Sign in

IAM

Iambic Therapeutics, Inc.

Iambic Therapeutics, Inc. is an American biological products company based in San Diego.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerIAM1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersSan Diego, California1
  • Incorporated inDE2
  • Business address5627 Oberlin Drive, Suite 120, San Diego, Ca 921212
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorFred Manby named Oct 12, 2023 to Sep 9, 20263
  • Executive OfficerMichael Secora named Nov 21, 2025 to Sep 9, 20263
  • Executive OfficerNeil Josephson named Jun 6, 2024 to Sep 9, 20263
  • Executive OfficerPete Olson named Nov 21, 2025 to Sep 9, 20263
  • Executive Officer, DirectorThomas Miller named Oct 12, 2023 to Sep 9, 20263
  • Executive OfficerTabbert Teng named Oct 12, 2023 to Jun 6, 20244
  • Executive OfficerChao Zhang named Oct 12, 20235
  • DirectorEvan Rachlin named Oct 12, 2023 to Sep 9, 20263
  • DirectorJishnu Bhattacharjee named Oct 12, 2023 to Sep 9, 20263
  • DirectorKurt von Emster named Oct 12, 2023 to Sep 9, 20263
  • DirectorMary Tagliaferri named Nov 21, 2025 to Sep 9, 20263
  • DirectorR. Jacob Vogelstein named Oct 12, 2023 to Sep 9, 20263
  • DirectorSamit Hirawat named Sep 9, 20263
  • DirectorShalini Sharp named Nov 21, 2025 to Sep 9, 20263
  • DirectorWilliam Rastetter named Oct 12, 2023 to Sep 9, 20263

Filings

29 filings to the SEC since October 2021: 13 insider forms, 7 private raises, 9 other. The latest 20:

  1. Oct 15, 2026424B4 EDGAR
  2. Oct 15, 2026S-8 EDGAR
  3. Oct 14, 2026EFFECT EDGAR
  4. Oct 14, 20263 EDGAR
  5. Oct 14, 20263 EDGAR
  6. Oct 14, 20263 EDGAR
  7. Oct 14, 20263 EDGAR
  8. Oct 14, 20263 EDGAR
  9. Oct 14, 20263 PRIMARY DOCUMENT EDGAR
  10. Oct 14, 20263 EDGAR
  11. Oct 14, 20263 EDGAR
  12. Oct 14, 20263 EDGAR
  13. Oct 14, 20263 EDGAR
  14. Oct 14, 2026CERT EDGAR
  15. Oct 14, 20263 EDGAR
  16. Oct 14, 20263 EDGAR
  17. Oct 14, 20263 EDGAR
  18. Oct 13, 20268-A12B EDGAR
  19. Oct 8, 2026S-1/A EDGAR
  20. Sep 21, 2026S-1 EDGAR

The 29 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Aug 14, 2026Raised $66 million in a private offering of debt Form D: $66.5 million offered in all Form D
  2. Apr 1, 2026Raised $27.8 million in a private offering of equity Form D: $50 million offered in all Form D
  3. Nov 6, 2025Raised $99.3 million in a private offering of equity Form D: $125 million offered in all Form D
  4. Apr 15, 2024Raised $38.4 million in a private offering of equity Form D: $50 million offered in all Form D
  5. Sep 29, 2023Raised $103.2 million in a private offering of equity Form D: $110 million offered in all Form D

SEC filer profile

How Iambic Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARIambic Therapeutics, Inc.1
  • CIK0001997038
  • Employer ID (EIN)84-33641681
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address5627 Oberlin Drive, Suite 120, San Diego, CA 921211
  • Phone(626) 592-25201
  • On EDGAR sinceOct 12, 20231
  • Filings29 in all: 3 (13), D (5), D/A (2), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), DRS/A (1)1
    All 12 form types

    EFFECT (1), S-1 (1), S-1/A (1), S-8 (1)

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5